Summit Partners Public Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Summit Partners Public Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-280,000	Closed	-$17.2M	–	99
2018 Q3	$17.2M	Buy	280,000 +110,000	+65%	+$7.07M	1.17%	28
2018 Q2	$11.5M	Buy	170,000 +50,000	+42%	+$2.8M	1.28%	23
2018 Q1	$6.51M	Buy	+120,000	New	+$6.71M	0.92%	44
2016 Q4	–	Sell	-45,000	Closed	-$1.7M	–	119
2016 Q3	$1.7M	Buy	+45,000	New	+$992K	0.28%	88
2015 Q3	–	Sell	-150,000	Closed	-$2.65M	–	73
2015 Q2	$2.65M	Buy	+150,000	New	+$2.75M	0.93%	42

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Summit Partners Public Asset Management's AERI Position: Q4 2018 in Review

Summit Partners Public Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 280,000 shares — an estimated $17.2M sold.

Summit Partners Public Asset Management first reported a position in AERI in Q2 2015 and held it in 5 quarters. The position peaked at $17.2M in Q3 2018. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Summit Partners Public Asset Management reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Summit Partners Public Asset Management sold 280,000 Aerie Pharmaceuticals shares in Q4 2018, an estimated $17.2M.
Summit Partners Public Asset Management first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Summit Partners Public Asset Management's Aerie Pharmaceuticals position peaked at $17.2M in Q3 2018.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.